Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10407368 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL5597841 | 0.83 | CES2 (0.39) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL3145510 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPTGAAL3MBTL1 | |
| SCHEMBL4735612 | 0.82 | ALDH1A1 (0.54) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL7134588 | 0.82 | TSHR (0.54) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL6075761 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL619877 | 0.80 | ALDH1A1 (0.52) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL162322 | 0.80 | MAPT (0.52) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL6555382 | 0.80 | MAPT (0.52) | KDM4EALDH1A1TSHRMAPTHSD17B10 | |
| SCHEMBL405123 | 0.80 | KDM4E (0.52) | KDM4EALDH1A1TSHRMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| CN-118222491-B | Method for improving in-vitro development capacity of small amount of frozen immature oocytes | 云南省畜牧兽医科学院 | 2024-07-26 | — | — | CN | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| CN-118222491-A | Method for improving in-vitro development capacity of small amount of frozen immature oocytes | 云南省畜牧兽医科学院 | 2024-06-21 | — | — | CN | disclosed |
| CN-113207298-B | Technique for preparing myocardial cell aggregate for improving survival rate under freezing preservation and hypoxia condition | T&R碧欧法博有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| CN-113207298-A | Preparation technology of myocardial cell aggregate for improving survival rate under cryopreservation and hypoxia conditions | T&R碧欧法博有限公司 | 2021-08-03 | — | — | CN | disclosed |
| EP-0888338-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5798276-A | DETECTING COMPLEMENTARY MEMBER OF SPECIFIC BINDING PAIR USING FLUORESCENT CONJUGATE | MOLECULAR PROBES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| WO-1997030991-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5652363-A | TREATING PLATELET ACTIVATING FACTOR MEDIATED DISEASES | C.D. SEARLE & CO. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0307817-A1 | Double reacting dyes and benzyl sulfonyl intermediates | BASF Aktiengesellschaft (DE) | 1989-03-22 | — | — | EP | disclosed |
| EP-0038541-B1 | NOVEL PRODRUGS OF BIOLOGICALLY ACTIVE AGENTS CONTAINING MERCAPTO GROUPS, PROCESS FOR PREPARING AND THERAPEUTICALLY EFFECTIVE COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1986-08-13 | — | — | EP | disclosed |
| US-4443435-A | ANTICARCINOGENS, HYPOTENSIVE AGENTS, HYPERTHYROIDISM | MERCK & CO., INC. (US) | 1984-04-17 | — | — | US | disclosed |
| EP-0038541-A1 | Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same | MERCK & CO. INC. (US) | 1981-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | KDM4E 1773/4885ALDH1A1 133/4885TSHR 766/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | KDM4E 1773/4885ALDH1A1 133/4885TSHR 766/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | KDM4E 2141/4885ALDH1A1 161/4885TSHR 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.